Skip to content

Effectiveness and safety evaluation of Flurbiprofen Gel Patch and Etoricoxib Tablets in the treatment of osteoarthritis - a prospective randomized controlled study

Effectiveness and safety evaluation of Flurbiprofen Gel Patch and Etoricoxib Tablets in the treatment of osteoarthritis - a prospective randomized controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075288
Enrollment
Unknown
Registered
2023-08-31
Start date
2021-03-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Aripiprazole tablet Group:Take Eriscimab tablets orally at a dose of 0.1 twice daily

Sponsors

The First People's Hospital of Shuangliu District, Chengdu City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age > 40 years old; diagnosed with osteoarthritis, experiencing joint pain symptoms, and a VAS score of 70mm= at baseline period =30mm; no oral or topical non-steroidal analgesics, opioid analgesics or glucosamine drugs were used within the week prior to enrollment; no history of bleeding, asthma, severe heart/liver/kidney dysfunction or allergy to non-steroidal drugs; patients are willing and able to provide signed informed consent before any study-related procedures.

Exclusion criteria

Exclusion criteria: Pregnant and lactating women or women of childbearing age who are planning to conceive; patients known to be allergic to non-steroidal anti-inflammatory drugs; patients who have participated in other drug clinical trials within the past month; patients who have received intra-articular injection therapy for joint cavity within the past month; patients who have received steroid treatment within the past month; patients who have undergone knee or hip surgery causing pain or affecting joint function in the 3 months prior to enrollment; other concurrent diseases or complications that may affect efficacy observation (such as local skin damage, infection, rash); Patients with aspirin-induced asthma or a history of bronchial asthma, coronary artery bypass grafting (CABG) perioperative period patients, those with a history of gastrointestinal bleeding or perforation after using non-steroidal anti-inflammatory drugs, active digestive tract ulcers/bleeding, or those with a history of recurrent ulcers/bleeding. Severe heart failure.

Design outcomes

Primary

MeasureTime frame
VAS score;

Secondary

MeasureTime frame
Knee joint function (WOMAC) and Lysholm score, shoulder joint function score were evaluated using the Constant-Murley Shoulder Assessment Form.;SF-36 Health Survey;

Countries

China

Contacts

Public ContactZhong Gang

Department of Orthopedics, First People's Hospital of Shuangliu District, Chengdu City; West China Hospital of Sichuan University

zg730927@163.com18980602092

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026